A Phase I Study of EC90 With GPI-0100 Adjuvant Followed by EC17 With Cytokines (Interleukin-2 [IL-2] and Interferon-alpha [IFN-alpha]) in Patients With Refractory or Metastatic Cancer

Inclusion Criteria:

- Have a histologically confirmed diagnosis of metastatic or refractory cancer for
which there are no effective standard therapeutic options available, (Note: for
patients accrued at Southern Illinois University, a diagnosis of renal (i.e., kidney)
carcinoma is required.)

- Have signed an Institutional Review Board (IRB) approved informed consent form (ICF)
prior to performing any study evaluation/procedures

- Be > or = 18 years of age and women must either be 1) not of childbearing potential
or 2) have a negative serum pregnancy test within 7 days prior to commencing
treatment. Patients are considered not of childbearing potential if they are
surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation or
bilateral oophorectomy) or they are postmenopausal (12 consecutive months of
amenorrhea [lack of menstruation])

- (If applicable) Have completed prior cytotoxic chemotherapy, radiotherapy or
immunotherapy or experimental therapy > or = 30 days prior to the study enrollment,
and recovered form associated toxicities

- Have an Eastern Cooperative Oncology Group (ECOG) score of < or = 2, and an
anticipated life expectancy of at least 6 months

- Have adequate hematologic function, as defined by an absolute or calculated
neutrophil count > or = 1500/microL, platelet count > or = 100000/microL, lymphocyte
count > or = 500/microL, and hemoglobin level > or = 10 g/dL. Patients may not
receive prophylactic transfusion in order to qualify for trial eligibility

- Have adequate renal function, as defined by a documented serum creatinine of < or =
2.0mg/dL. Greater than "1+" proteinuria will require microscope evaluation and the
results discussed with the medical monitor prior to patient enrollment; or if serum
creatine is >2.0, patient must have an actual or calculated 24-hour creatinine
clearance of >60mL/min and no obvious evidence of concurrent medullary cystic disease
or obstructive uropathy

- Have adequate hepatic function, as defined by a total bilirubin level < or = 1.5 x
upper limit of normal (ULN) and alkaline phosphatase, aspartate transaminase (AST),
and alanine transaminase (ALT) levels < or = 2.5 x ULN. If alkaline phosphatase is
outside of these parameters and is due to bone metastases (as verified by the
assessment of isoenzymes), then the patient is eligible.

Exclusion Criteria:

- Have previously participated in a FolateImmune trial

- Have a history of severe hypersensitivity (grade 3 - 4 allergic reaction) to
fluorescein or any drug, radiologic contrast agent, insect bite, food, cytokines, or
any other agent; or have received fluorescein within 30 days of the study.

- Have medical conditions that preclude the use of IL-2 or IFN-alpha. These conditions
include but are not limited to, diabetes mellitus with a history of progression to
diabetic ketoacidosis, history of severe coagulation disorder, psoriasis,
sarcoidosis, retinal hemorrhage, symptomatic pulmonary disease, heart failure (> or =
New York Heart Association NYHA class II), or transplant requiring immunosuppressive
therapy

- Be pregnant or breast-feeding

- Be currently receiving an experimental drug, or used an experimental device within 30
days of study entry

- Be currently undergoing chemotherapy, anticancer hormonal therapy, and/or therapy
with immunosuppressant agents

- Have any concomitant malignancy with the exception of basal cell or squamous cell
carcinoma of skin

- Have radiographically documented evidence of current brain metastases, a history of
stem cell transplant, immunodeficiency, and/or a medical or psychiatric illness (that
in the investigator's opinion, would prevent adequate compliance with study therapy
or evaluation of the endpoints)